BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Argus Health
AstraZeneca
Merck
Moodys
Fish and Richardson
Federal Trade Commission
Queensland Health
Novartis

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019668

« Back to Dashboard

NDA 019668 describes CARDURA, which is a drug marketed by Pfizer and is included in two NDAs. It is available from three suppliers. Additional details are available on the CARDURA profile page.

The generic ingredient in CARDURA is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Summary for 019668
Tradename:CARDURA
Applicant:Pfizer
Ingredient:doxazosin mesylate
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 019668
Mechanism of ActionAdrenergic alpha-Antagonists
Medical Subject Heading (MeSH) Categories for 019668
Suppliers and Packaging for NDA: 019668
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARDURA doxazosin mesylate TABLET;ORAL 019668 NDA Roerig 0049-2750 0049-2750-41 100 BLISTER PACK in 1 CARTON (0049-2750-41) > 1 TABLET in 1 BLISTER PACK
CARDURA doxazosin mesylate TABLET;ORAL 019668 NDA Roerig 0049-2750 0049-2750-66 100 TABLET in 1 BOTTLE (0049-2750-66)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Nov 2, 1990TE:ABRLD:Yes

Expired US Patents for NDA 019668

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Deloitte
Covington
Fish and Richardson
Express Scripts
US Army
Farmers Insurance
Teva
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot